EML4 and non-small cell lung carcinoma: However, the frequency of EML4-ALK in the Western population is only around 1–7% [7], which means that more than 40% of non-small cell lung cancer (NSCLC) patients without EGFR or EML4-ALK mutations are left without any available targeted therapy [7].